Biopsy is a surgical removal of tissue from an organ to decide the presence or extent of a disease,  commonly cancerous and inflammatory conditions. According to Marketstack, the Global Biopsy Devices Market is expected to grow considerably during the forecasted period. Factors such as the growing burden of prevalence of various cancers such as lung, breast cancer and other types of cancer are expected to drive the Biopsy Devices market in the forecasted period. Further, growth determinants, such as demand for minimally invasive biopsy procedures and the expanding healthcare sector, are expected to drive the Biopsy Devices market in the forecasted period. Furthermore, the different types of technologies and products, such as biopsy guiding systems, needle-based biopsy guns, and vacuum-assisted devices, are expected to drive the Biopsy Devices market in the forecasted period. However, the high cost of biopsy devices and, clinical issues in core needle biopsy, increased complaints of breast cancer screening procedures are projected to hinder the biopsy devices market in the forecast period.

The growing global diagnosis of cancer patients has significantly increased the demand for accurate and convenient diagnostic methods, particularly for the early detection of tumours. A biopsy is a confirming process that helps in early cancer/tumour diagnosis, which promotes quick recovery, surged survival, and a reduction in morbidity and death. Medical professionals advise a breast biopsy for the early diagnosis of breast cancer. Various governmental and private organizations, commercial enterprises, and medical facilities are working on innovative initiatives to raise public awareness of breast cancer and the benefits of early detection on health. The applications of biopsy devices are diverse and cover a wide range of medical disciplines. In oncology, biopsy devices are extensively used for the diagnosis and staging of cancer. They aid in identifying cancerous tumours, determining their characteristics, and assessing their extent of spread. Biopsy devices are employed in different body areas, including the breast, lung, liver, prostate, skin, and lymph nodes, to collect tissue samples for accurate cancer diagnosis. Robotic platforms, surgical navigation systems, and artificial intelligence are in high need due to their accuracy and efficiency. Using robotics in MRI systems can localize breast abnormalities and improve procedural efficacy. Vendors are also developing AI-integrated solutions to help doctors analyze breast cancer and reduce human errors.

Additionally, biopsy devices monitor cancer progression and treatment response, enabling healthcare professionals to adjust therapies based on the obtained tissue samples. The increasing number of cancer cases encourages the key market players to develop more effective, advanced, and safe biopsy procedures. Apart from this, invasive medical procedures provide various benefits, which is increasing their popularity. These medical procedures help the patients recover quickly and are less traumatic. Many reports stated that invasive surgeries replace minimally invasive surgeries and offer higher patient satisfaction. Breast cancer can be detected effectively and promptly using modern biopsy tools. The demand for the usage of biopsy equipment has increased globally due to increased public awareness of disease screening and technological advancements in biopsy devices.

North America is the dominating revenue contributor in the market. The market players in the region will continue to account for a substantial market share throughout the forecasted period. The number of biopsies performed in the U.S. is also the highest, helping expand the overall market. Minimally invasive medical procedures provide several advantages, thus bolstering their popularity. Such practices result in the quicker recovery of patients and are less traumatic. Research results published by producers suggest that minimally invasive surgeries rapidly replace invasive surgeries and provide higher patient satisfaction levels. Spiralling demand for less invasive surgeries and disposable biopsy devices is anticipated to fuel the industry's growth. Technologically advanced biopsy guidance systems, like vacuum-assisted guns, are increasingly popular among patients and healthcare providers. The growing geriatric population base and the cost-effective and advanced devices are predicted to boost the market's growth further.

Needle-based biopsy holds a significant share in the market owing to the elevating demand for these instruments for obtaining samples from soft tissues of internal organs, like kidneys, breasts, and lungs. A needle biopsy may be called for when a doctor feels an abnormal lump or when imaging scans show the existence of abnormalities in an area of the body. Lumps of the breast, thyroid or lymph nodes are often checked using a needle biopsy. Needle biopsy may take tissue or fluid samples from bones and other organs, such as the lungs or livers. Biopsy guidance systems refer to the advanced imaging technologies and tools used to precisely locate and target specific areas for biopsy procedures. These systems enhance accuracy, reduce invasiveness, and improve patient outcomes. They are typically integrated with imaging modalities such as ultrasound, magnetic resonance imaging (MRI), computed tomography (C.T.), or stereotactic imaging. One key growth driver in the biopsy guidance systems segment is the increasing adoption of minimally invasive techniques. These techniques offer several benefits over traditional open surgical biopsies, including reduced patient discomfort, shorter recovery times, and lower healthcare costs. Biopsy guidance systems enable physicians to target lesions or abnormalities within the body precisely, facilitating the performance of minimally invasive biopsies with higher precision and accuracy.

The market key players are Cardinal Health Inc., Hologic, Inc., Danaher Corporation, CONMED Corporation, and Cook Medical.

In September 2023, Boston Scientific Corporation announced the U.S. FDA approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device. Designed to advance further the procedural performance and safety of the WATCHMAN technology, which is indicated to minimize stroke risk in patients with non-valvular atrial fibrillation (NVAF) who demand an alternative to oral anticoagulation therapy, the device now has characteristics of a polymer coating, visualization markers, and a wider size matrix to treat a more comprehensive range of patients.

Our Global Biopsy Devices Market report provides deep insight into the current and future state of the market across various regions. Also, the study comprehensively analyzes the Biopsy Devices market by segments based on the Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires, Other Products), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRi-guided biopsy, Other Guidance Techniques), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, Other Applications), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), and by Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers & includes emerging market trends, market developments, market opportunities, market size, market analysis, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of prominent companies, including their market share and projects.